CAH's specialty flywheel strategy links distribution, MSOs and biopharma services, boosting partnerships, drug launches and recurring revenue potential.
Cardinal Health $CAH’s CAH evolving “specialty flywheel” strategy is emerging as a powerful engine for long-term growth, driven by the integration of distribution, MSO platforms and biopharma services into a unified ecosystem. Management emphasized that growth in specialty is no longer isolated but increasingly interconnected, with each capability reinforcing the other across the value chain.
At the core of this strategy lies the seamless integration of specialty distribution, physician-facing MSOs and upstream biopharma services. Cardinal Health’s MSO platforms — spanning oncology, autoimmune and urology — anchor downstream physician engagement, while its distribution infrastructure ensures efficient product flow. This is complemented by biopharma services like Sonexus and 3PL capabilities, which support drug commercialization and patient access programs.
This dual positioning — upstream with manufacturers and downstream with providers and patients — is central to the flywheel effect. Cardinal Health is increasingly partnering with manufacturers on product launches, supporting roughly half of new specialty therapies requiring 3PL services, while also expanding patient access through hub services that manage more than 1 million patients. These capabilities enhance visibility across the therapy lifecycle, creating incremental value for both suppliers and providers.
The integration of these platforms is driving cross-segment growth synergies. MSOs enhance distribution volumes, while biopharma services strengthen manufacturer relationships, creating a virtuous cycle that feeds back into distribution and access programs. Management noted that this interconnected model is already improving performance across the specialty business, rather than relying on any single growth lever.
Cardinal Health is gaining enhanced credibility with manufacturers, supported by its end-to-end capabilities and consistent execution. This credibility is translating into increased participation in drug launches, deeper partnerships and recurring revenue streams.
Overall, the specialty flywheel positions Cardinal Health to capture a larger share of the specialty value chain. By leveraging its integrated ecosystem, the company is building a scalable, high-margin growth platform that could sustain long-term earnings expansion.
Apart from Cardinal Health, other two leading medical-distributors — McKesson $MCK MCK and Cencora COR — are also focusing their strategy on specialty drugs and services. This strategy has driven strong growth across the country’s top distributors over the past couple of years. The company believes that specialty will be a key top-line driver, along with a higher-margin mix going forward.
McKesson is positioning specialty services at the center of its long-term growth strategy, with oncology and multispecialty platforms acting as integration hubs. Its oncology network has expanded to roughly 3,400 providers, supported by continued growth in biopharma services and specialty distribution.
Through the integration of assets like Florida Cancer Specialists and PRISM Vision, McKesson is enhancing provider engagement and care delivery. This ecosystem allows the company to capture value across the care continuum, positioning specialty as a primary driver of long-term growth.
Cencora is advancing a similarly integrated specialty strategy, combining distribution scale with physician-facing platforms and biopharma services. COR emphasized strong performance in its U.S. Healthcare Solutions segment, supported by specialty drug demand and the expansion of MSO platforms, such as OneOncology and Retina Consultants of America.
The company is leveraging these platforms to strengthen relationships with providers while enhancing its value proposition to manufacturers. By integrating distribution, clinical networks and commercialization support, Cencora is building a vertically aligned specialty ecosystem. This approach is expected to drive higher-margin growth and position specialty as a central contributor to COR’s long-term earnings trajectory.
Shares of CAH have gained 2.2% so far this year against the industry’s 4.4% decline.
Image Source: Zacks Investment Research
From a valuation standpoint, Cardinal Health trades at a forward price-to-earnings ratio of 18.98, above the industry average. It is also higher than its five-year median of 13.52. CAH carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Cardinal Health’s fiscal 2026 earnings implies a 25.1% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
McKesson Corporation (MCK): Free Stock Analysis Report
Cencora, Inc. (COR): Free Stock Analysis Report
Join 500,000+ readers who start their day with Quartz.
By subscribing, you agree to our Terms of Service and Privacy Policy.
